ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

172
Analysis
Health CareChina
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
Refresh
03 Mar 2021 09:28

CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?

This article analyzed CanSino's core technology platforms, key products in the pipeline, insights on the products and core competitiveness and also...

Logo
285 Views
Share
01 Mar 2021 09:25

China Healthcare Weekly (Feb.26)

This article analyzed the VBP policy on Chinese patent medicines, the growth potential in the chemiluminescence and intensive procurement of IVD...

Logo
223 Views
Share
28 Feb 2021 21:58

Quiddity Weekly H/A: Strong Dispersion, Strong Alpha; Brokers Beat Banks

Great alpha last week as shorts beat by 48bp, longs beat by 46bp. Southbound saw one really big sell day, but on the week, buying continued apace...

Logo
227 Views
Share
28 Feb 2021 09:55

Beijing Wantai Biological (603392.CH) - After A 3839% Rally, Let's Look at Some Concerns

Behind the outstanding performance in stock price,there could be some concerns that deserve to pay attention to in business side, financial...

Logo
248 Views
Share
21 Feb 2021 09:22

Quiddity Weekly H/A: High Volatility in Materials and Industrials and Spreads Over Lunar New Year

H/A spreads have been reasonably volatile over the CNY period, but again they net narrowed over two weeks. There are still several sectors where...

Logo
138 Views
Share
x